Congress' Year-End Appropriations Package Brings FDA Legislative Changes, Leaves Unresolved Policy Issues | Akin Gump Strauss Hauer & Feld LLP

In a break with past precedent, last year’s Food and Drug Administration (FDA) user fee reauthorization legislation did not contain significant FDA policy changes. Although the Senate...

Related Keywords

United States , ,Akin Gump Strauss Hauer Feld ,Rare Disease Endpoint Advancement Pilot Program ,Device Manufacturer Communications With Payors ,Drug Administration ,Pharmaceuticals For Children ,Exchange Of Product Information Prior To Approval ,Public Health Service ,Office Of Critical Foods ,Clinical Laboratory Improvement Amendments ,Senate Appropriations ,Products Grants Program ,Government Accountability Office ,Senate Health ,Program Reauthorizations ,Akin Gump Strauss Hauer ,Consolidated Appropriations Act ,President Biden ,Drug Omnibus Reform Act ,Century Cures ,Existing Viruses ,Emerging New Threats ,Pandemics Act ,All Hazards Preparedness Act ,Rare Disease ,Biosimilar Exclusivity ,Public Health Service Act ,Cosmetic Act ,Equivalence Determinations ,Product Information Prior ,Formulary Committees ,Similar Entities ,Payor Guidance ,Change Control Plans ,Dual Submissions ,World Evidence ,Foreign Governments ,Cosmetics Regulation Act ,Critical Foods ,Food Safety ,Orphan Drug Act ,Best Pharmaceuticals ,Children Act ,Critical Path Public Private Partnership ,Pediatric Device Consortia Grants ,Appropriations Act ,